142 related articles for article (PubMed ID: 1756327)
21. Application of hypothermia to autologous stem cell purging.
Miyagi K; Yamazaki T; Tsujino I; Takahashi N; Koya Y; Masutani M; Sawada U; Horie T
Cryobiology; 2001 May; 42(3):190-5. PubMed ID: 11578118
[TBL] [Abstract][Full Text] [Related]
22. [Use of photodynamic therapy for elimination of residual leukemic cells in autologous transplants of hematopoietic progenitor cells].
Hrkal Z; Grebenová D; Cajthamlová H; Soucek J; Bartosová J; Fuchs O; Marinov I; Kobylka P; Klamová H; Sponerová D
Cas Lek Cesk; 2002 Sep; 141 Suppl():41-6. PubMed ID: 12428422
[TBL] [Abstract][Full Text] [Related]
23. Comparison of in vitro inhibition of etoposide (VP16) on leukemic and normal myeloid, erythroid clonogenic cells.
Lagneaux L; Marie JP; Delforge A; Socquet M; Thevenin D; Zittoun R; Stryckmans P
Exp Hematol; 1989 Aug; 17(7):843-6. PubMed ID: 2753092
[TBL] [Abstract][Full Text] [Related]
24. Goralatide (AcSDKP) selectively protects murine hematopoietic progenitors and stem cells against hyperthermic damage.
Wierenga PK; Konings AW
Exp Hematol; 1996 Feb; 24(2):246-52. PubMed ID: 8641348
[TBL] [Abstract][Full Text] [Related]
25. Eilatin: a novel marine alkaloid inhibits in vitro proliferation of progenitor cells in chronic myeloid leukemia patients.
Einat M; Lishner M; Amiel A; Nagler A; Yarkorli S; Rudi A; Kashman Y; Markel D; Fabian I
Exp Hematol; 1995 Dec; 23(14):1439-44. PubMed ID: 8542929
[TBL] [Abstract][Full Text] [Related]
26. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
[TBL] [Abstract][Full Text] [Related]
27. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S
Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
[TBL] [Abstract][Full Text] [Related]
28. Role of cytoprotective mechanisms in the photochemical purging of autologous bone marrow grafts.
Yamazaki T; Sato Y; Sieber F
Exp Hematol; 1997 Jul; 25(7):629-37. PubMed ID: 9216739
[TBL] [Abstract][Full Text] [Related]
29. Prolonged exposure to cytosine arabinoside in the presence of hematopoietic growth factors preferentially kills leukemic versus normal clonogenic cells.
Van Der Lely N; De Witte T; Muus P; Raymakers R; Preijers F; Haanen C
Exp Hematol; 1991 May; 19(4):267-72. PubMed ID: 2055291
[TBL] [Abstract][Full Text] [Related]
30. Photoradiation methods for purging autologous bone marrow grafts.
Gulati S; Atzpodien J; Lemoli RM; Shimazaki C; Clarkson B
Prog Clin Biol Res; 1990; 333():87-102. PubMed ID: 2137934
[TBL] [Abstract][Full Text] [Related]
31. Prompt haemopoietic reconstitution following hyperthermia purged autologous marrow and peripheral blood stem cell transplantation in acute myeloid leukaemia.
Herrmann RP; O'Reilly J; Meyer BF; Lazzaro G
Bone Marrow Transplant; 1992 Sep; 10(3):293-5. PubMed ID: 1358379
[TBL] [Abstract][Full Text] [Related]
32. Effect of recombinant human stem cell factor on mafosfamide-treated bone marrow clonogenic cells.
Carlo-Stella C; Mangoni L; Almici C; Caramatti C; Rizzoli V
Stem Cells; 1993 Jul; 11 Suppl 2():170-4. PubMed ID: 7691323
[TBL] [Abstract][Full Text] [Related]
33. Purging leukemia remission marrows with alkyl-lysophospholipids, preclinical and clinical results.
Vogler WR; Olson AC; Berdel WE; Okamoto S; Glasser L
Prog Clin Biol Res; 1990; 333():1-18; discussion 19-20. PubMed ID: 2308973
[TBL] [Abstract][Full Text] [Related]
34. Pre-clinical evaluation of anti-lacto-N-fucopentaose III (CD15) monoclonal antibodies for ex vivo bone marrow purging in acute myeloid leukemia.
Guyotat D; Shi ZH; Campos L; Rabat M; Bonnier S; Poncelet P; Laurent JC; Fiere D
Bone Marrow Transplant; 1990 Dec; 6(6):385-90. PubMed ID: 1982926
[TBL] [Abstract][Full Text] [Related]
35. In vitro cytotoxicity of VP-16-213 and nitrogen mustard: agonistic on tumor cells but not on normal human bone marrow progenitors.
Lemoli RM; Gulati SC
Exp Hematol; 1990 Oct; 18(9):1008-12. PubMed ID: 2397748
[TBL] [Abstract][Full Text] [Related]
36. [Selective photodynamic destruction of leukemic cells].
Hrkal Z; Cajthamlová H; Grebenová D; Bartosová J; Klamová H; Marinov J
Cas Lek Cesk; 2000 Mar; 139(5):148-54. PubMed ID: 10838736
[TBL] [Abstract][Full Text] [Related]
37. The sensitivity of leukemic bone marrow to simvastatin is lost at remission: a potential purging agent for autologous bone marrow transplantation.
Newman A; Clutterbuck RD; DeLord C; Powles RL; Catovsky D; Millar JL
J Investig Med; 1995 Jun; 43(3):269-74. PubMed ID: 7614073
[TBL] [Abstract][Full Text] [Related]
38. Differential effect of type I interferons on hematopoietic progenitor cells: failure of interferons to inhibit IL-3-stimulated normal and CML myeloid progenitors.
Després D; Goldschmitt J; Aulitzky WE; Huber C; Peschel C
Exp Hematol; 1995 Dec; 23(14):1431-8. PubMed ID: 8542928
[TBL] [Abstract][Full Text] [Related]
39. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
[TBL] [Abstract][Full Text] [Related]
40. Treatment with interferon-alpha preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors (CFU-GM) from patients with chronic myeloid leukemia but spares normal CFU-GM.
Gordon MY; Marley SB; Lewis JL; Davidson RJ; Nguyen DX; Grand FH; Amos TA; Goldman JM
J Clin Invest; 1998 Aug; 102(4):710-5. PubMed ID: 9710439
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
